Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC.
J Acquir Immune Defic Syndr. 2014 Dec 1;67 Suppl 4(Suppl 4):S188-94. doi: 10.1097/QAI.0000000000000372.
BACKGROUND: "Option B+" is a World Health Organization-recommended approach to prevent mother-to-child HIV transmission whereby all HIV-positive pregnant and lactating women initiate lifelong antiretroviral therapy (ART). This review of early Option B+ implementation experience is intended to inform Ministries of Health and others involved in implementing Option B+. METHODS: This implementation science study analyzed data from 11 African countries supported by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) to describe early experience implementing Option B+. Data are from 4 sources: (1) national guidelines for prevention of mother-to-child HIV transmission and Option B+ implementation plans, (2) aggregated service delivery data between January 2013 and March 2014 from EGPAF-supported sites, (3) field visits to Option B+ implementation sites, and (4) relevant EGPAF research, quality improvement, and evaluation studies. RESULTS: Rapid adoption of Option B+ led to large increases in percentage of HIV-positive pregnant women accessing ART in antenatal care. By the end of 2013, most programs reached at least 50% of HIV-positive women in antenatal care with ART, even in countries using a phased approach to implementation. Scaling up Option B+ through integrating ART in maternal and child health settings has required expansion of the workforce, and task shifting to allow nurse-led ART initiation has created staffing pressure on lower-level cadres for counseling and community follow-up. Complex data collection needs may be impairing data quality. DISCUSSION: Early experiences with Option B+ implementation demonstrate promise. Continued program evaluation is needed, as is specific attention to counseling and support around initiation of lifetime ART in the context of pregnancy and lactation.
背景:“Option B+”是世界卫生组织推荐的一种预防母婴传播艾滋病毒的方法,即所有艾滋病毒阳性的孕妇和哺乳期妇女都应开始终身抗逆转录病毒治疗(ART)。本研究旨在为卫生部门和其他参与实施 Option B+的人员提供早期 Option B+实施经验的回顾,以提供信息。
方法:本实施科学研究分析了伊丽莎白·格拉泽儿科艾滋病基金会(EGPAF)支持的 11 个非洲国家的数据,以描述实施 Option B+的早期经验。数据来自 4 个来源:(1)预防母婴传播艾滋病毒的国家指南和 Option B+实施计划;(2)EGPAF 支持的地点在 2013 年 1 月至 2014 年 3 月之间汇总的服务提供数据;(3)对 Option B+实施地点的实地考察;(4)相关的 EGPAF 研究、质量改进和评估研究。
结果:快速采用 Option B+导致接受产前护理的艾滋病毒阳性孕妇接受抗逆转录病毒治疗的比例大幅增加。到 2013 年底,大多数方案至少为 50%的艾滋病毒阳性孕妇提供了产前护理中的抗逆转录病毒治疗,即使在实施分阶段方法的国家也是如此。通过将抗逆转录病毒治疗整合到妇幼保健环境中,扩大 Option B+的规模需要扩大劳动力,将任务转移到允许护士主导抗逆转录病毒治疗的启动,这给低级别干部的咨询和社区随访带来了人员压力。复杂的数据收集需求可能会影响数据质量。
讨论:早期实施 Option B+的经验表明了希望。需要继续进行方案评估,特别是需要关注在妊娠和哺乳期开始终生抗逆转录病毒治疗的咨询和支持。
J Acquir Immune Defic Syndr. 2014-12-1
MMWR Morb Mortal Wkly Rep. 2013-3-1
Cochrane Database Syst Rev. 2010-3-17
South Afr J HIV Med. 2023-10-19
Trop Med Int Health. 2022-6
East Afr Health Res J. 2019
Afr J Lab Med. 2020-11-26
Front Public Health. 2020-10-28
Lancet. 2013-1-26
Bull World Health Organ. 2012-10-16